Bay State biotechs Sesen and Carisma blend together in bid to transform cancer treatment

Sesen Bio and privately held Carisma Therapeutics are merging, with plans to combine into a “well-funded” biotech that will operate under Carisma’s name and work to advance its engineered macrophages for cancer treatment.